213
Views
17
CrossRef citations to date
0
Altmetric
Original Articles

Biological studies and computational modeling of two new copper complexes derived from β-diketones and their nano-complexes

, , &
Pages 1697-1714 | Received 30 Jul 2018, Accepted 21 Mar 2019, Published online: 21 May 2019
 

Abstract

The present study was conducted to design and develop new complexes and their metal-based nanodrug (registered as Casiopeínas® for cancer) with a low toxicity, high efficiency, and high selectivity. First, complexes ([Cu(TTA)(bpy)2] (1) and [Cu(TTA)2(en)] (2) (TTA = 4,4,4-trifluoro-1-(2-furyl)-1,3-butanedione) were synthesized and characterized by X-ray diffraction studies, CHN analysis, conductivity measurements, FT-IR and UV-vis spectroscopy. Second, nanoparticles (NPs) of 3 and 4 with the average size of 63.04 and 85.39 nm were prepared with ultrasound. Scanning electron microscopy patterns of 3 and 4 showed irregular spherical and nanorod particles with spongy surface. Furthermore, the anticancer properties of compounds and nano-compounds were studied in MKN-45 cell line. Then, apoptosis studies were carried out utilizing AO/EB staining methods. Finally, to confirm the in vitro experimental data, the theoretical study was carried out by molecular docking studies. The results of DNA docking analysis revealed that 1 and 2 were inserted with DNA via the minor groove. The binding affinity monitors the order of 1 > 2, with a preference of binding to A-T over G-C base pairs sequences.

Acknowledgments

We thank Semnan University for supporting this study.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.